产品详情
In vitro (25°C) | DMSO | 9 mg/mL (21.85 mM) | |
Water | Insoluble | ||
Ethanol | Insoluble | ||
In vivo | 1% CMC Na | 19 mg/mL | |
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
0.1 mM | 24.28 mL | 121.4 mL | 242.8 mL |
0.5 mM | 4.86 mL | 24.28 mL | 48.56 mL |
1 mM | 2.43 mL | 12.14 mL | 24.28 mL |
5 mM | 0.49 mL | 2.43 mL | 4.86 mL |
*The above data is based on the productmolecular weight 411.86. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
目录号 | A11954 |
---|---|
作用机制 | Inhibitor (抑制剂) |
M. Wt | 411.86 |
Formula | C22H18FN3O2.HCl |
Purity | >99% |
Storage | Store lyophilized at -20ºC, keep desiccated. |
CAS No. | 324077-30-7 |
Synonyms | ZM323881 |
SMILES | CC1=CC(=C(C=C1O)NC2=NC=NC3=C2C=CC(=C3)OCC4=CC=CC=C4)F.Cl |
产品资料
产品标签
Product Questions
Product Questions
RAF265 (CHIR-265)
RAF265 (CHIR-265)是一种口服,高度选择性的RAF和VEGFR激酶抑制剂,可控制或正常化VEGFR-2,同时抑制B-raf和c-Raf…
CYC116 (CYC-116)
CYC116 (CYC-116)是一种有效的Aurora A/B抑制剂,Ki为8.0 nM/9.2 nM,对VEGFR2(Ki为44 nM)作用稍弱。
NVP-BAW2881
NVP-BAW2881是有效的选择性VEGFR抑制剂(血管内皮生长因子受体酪氨酸激酶抑制剂),IC50 为值9 nM,具有抑制…
Linifanib (ABT-869)
Linifanib (ABT-869)是一种结构新颖的有效RTK,VEGF和PDGF抑制剂,对人内皮细胞,PDGFR-β,KDR和CSF-1R的IC50分别为0.…
ZM 306416
ZM 306416 hydrochloride是一种VEGF受体酪氨酸激酶抑制剂,可抑制KDR(IC50 = 100 nM)和Flt(IC50 = 2 uM)酪氨酸激酶…
XL184 free base (Cabozantinib)
XL184 free base (Cabozantinib)是设计用来抑制多种受体酪氨酸激酶(特别是MET和VEGFR2)的小分子。
Motesanib Diphosphate (AMG-706)
Motesanib也称为AMG-706,是一种有效的ATP竞争性的VEGFR1/2/3抑制剂,IC50分别为2 nM/3 nM/6 nM;对Kit具有相似的抑制…